Logotipo de Valence
populares
Iniciar sesión
Loading data for ADPT — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

Adaptive Biotechnologies ...

NasdaqGS: ADPT · Precio en tiempo real · USD
24.74
+0.28 (1.14%)
Al cierre: Aug 18, 2026, 8:00 PM
24.56
+0.00%
Premercado: 4:00 AM

Adaptive Biotechnologies Corporation (ADPT) Stock Price, Analysis & Data

1.14%

No hay datos disponibles

Precio de compra17.86
Capitalización de mercado3.92B
Ingresos (TTM)308.08M
Beneficio neto (TTM)-63.85M
Beta2.09
EPS (TTM)-0.4
Ratio PER (TTM)n/a
Adelante PE-132.95
P/B (TTM)27.35
P/S (TTM)12.72
Earnings DateNov 4, 2026
Precio de venta24.75
Volumen1,743,593
Volumen medio (20D)2,931,406
Abierto24.27
Anterior Cerrar24.46
Rango del día24.00 - 24.95
Rango de 52 semanas11.92 - 26.16
analistan/a
Precio objetivon/a
Dividendosn/a
Fecha ex dividendon/a

Acerca de ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining num...

[Leer más]
Industria Diagnostics & Research
Sector Healthcare
IPO Fecha Jun 27, 2019
Empleados 624
Bolsa de Valores NasdaqGS
Símbolo bursátil ADPT
Sitio web https://www.adaptivebiotech.com
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Adaptive Biotechnologies fueron 276.98M, un aumento de 54.77% en comparación con 178.96M del año anterior. Las ganancias fueron -59.5M, una disminución de -62.69%.

Estados financieros

Sorpresa de resultados

Adaptive Biotechnologies ha publicado sus resultados trimestrales en Jul 29, 2026:
  • Ingresos de n/a falla las estimaciones por $0, con -100.00% Disminución interanual.
  • EPS de -0.25 falla las estimaciones por -0.12, con -47.06% Disminución interanual.

    • Próxima publicación de resultados

    Está previsto que Adaptive Biotechnologies Corporation publique sus resultados el Nov 4, 2026, durante el horario de mercado.
    Los analistas proyectan ingresos de ... Actualizar
    news image

    2 semanas hace · GuruFocus.com

    Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

    Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

    news image

    2 semanas hace · Zacks

    Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

    While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key m...

    news image

    2 semanas hace · Zacks

    Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

    Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

    news image

    2 semanas hace · MarketBeat

    Adaptive Biotechnologies Q2 Earnings Call Highlights

    Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year reve...

    news image

    3 semanas hace · Simply Wall St.

    Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In

    Investors are watching Adaptive Biotechnologies (ADPT) after forecasts pointed to a reduced quarterly loss of $0.13 per share and 12.6% revenue growth for the June 2026 quarter, alongside its track re...

    Página 1 de 2